A single pill taken once a week kept HIV suppressed as effectively as the daily regimen that is currently the global standard, according to phase 3 results published in the New England Journal of Medicine.
The trial tested a combination tablet of islatravir 2 mg and lenacapavir 300 mg in adults whose virus had already been suppressed for at least six months on daily therapy. At 48 weeks, the phase 3 ISLEND-1 results met the primary endpoint of noninferiority against once-daily bictegravir, emtricitabine and tenofovir alafenamide.
